Target Validation and Lead Discovery: From a Biological Claim to a Molecule
A target is worth pursuing only if changing it changes disease and if a molecule can reach it. This stop covers genetic and chemical validation, screening for hits, and the properties a hit has to gain before it counts as a lead.
What a learner can do afterwards
- Distinguish genetic validation of a target from chemical validation, and say what each leaves open
- Explain what a screening hit has to survive before anyone calls it a lead
- Relate potency, selectivity and exposure to whether a molecule can work in a body
1 · Read
Target validation asks whether changing a target changes disease, and whether a molecule can reach it. Genetic evidence shows the target matters in disease but leaves open whether a drug can reach and modulate it safely. Chemical evidence shows modulation is possible but leaves open whether patients benefit. A serious program wants both legs before spending at scale.
Drugs act by binding receptors, blocking transporters, or altering enzymes, and the dose response curve reveals much. Agonists push while antagonists block, and affinity decides who wins the seat at low doses. This binding logic is what chemical validation must demonstrate in cells, not just in a well.
A screening hit sits at the very start of a long road. Before anyone says lead, the hit must confirm in fresh assays, show dose response, survive counterscreens against related targets, dissolve well enough to test, and act in cells. Each gate removes artifacts that looked promising in one well.
Judge every candidate on three numbers together. Potency sets the concentration needed at the target. Selectivity sets how much hits elsewhere. Exposure sets whether free drug reaches that level in tissue and stays there. A brilliant binder with no exposure is a reagent, not a medicine.
Prove the target both ways, gate every hit hard, and demand potency with selectivity and exposure.
More to read
2.2 Pharmacokinetics and Pharmacodynamics
Pharmacokinetics follows what the body does to a molecule: absorption, distribution, breakdown, and clearance. Pharmacodynamics follows what the molecule does to the body: binding its target and triggering an effect. A candidate must survive both journeys to matter. This pair maps directly onto potency, selectivity, and exposure. Potency sets the concentration needed at the target. Selectivity sets how much hits elsewhere. Exposure sets whether free drug actually reaches that level in tissue and stays there. A brilliant binder with no exposure is a reagent, not a medicine.
1.2 Drug Sources, Forms, and Names
Medicines come from natural products, synthetic chemistry, and engineered proteins, and each source brings its own screening logic. Formulations then decide how the molecule meets the body: dissolved or solid, fast or slow, local or systemic. A screening hit sits at the very start of this road. Before anyone says lead, the hit must confirm in fresh assays, show dose response, survive counterscreens against related targets, dissolve well enough to test, and act in cells. Each gate removes artifacts that looked promising in one well.
14.1 Basic Principles of Pharmacology
Drugs act by binding receptors, blocking transporters, or altering enzymes, and the shape of the dose response curve reveals much. Agonists push, antagonists block, and affinity decides who wins the seat at low doses. Target validation asks a harder question than binding. Genetic evidence shows the target matters in disease, but leaves open whether a drug can reach and modulate it safely. Chemical evidence shows modulation is possible, but leaves open whether patients benefit. A serious program wants both legs before committing chemistry at scale.
2 · Watch
Take it off screen
Where it sits
Optional connections
8 questions wait behind this lesson, each with its answer explained. Every answer feeds the sky: stars light as they are learned, and dim when it is time to come back.